Literature DB >> 8222198

Prognosis and management of anterolateral myocardial infarction in patients with severe left main disease and cardiogenic shock. The left main shock syndrome.

R L Quigley1, C A Milano, L R Smith, W D White, J S Rankin, D D Glower.   

Abstract

BACKGROUND: To identify the determinants of survival in patients with severe (> 75%) stenosis of the left main coronary artery (LM) and an acute (48 hours) anterolateral myocardial infarction (AAMI), we retrospectively analyzed the course of 34 such patients who presented to our institution over the last decade. METHODS AND
RESULTS: LM disease was diagnosed arteriographically at presentation, and AAMI was determined by ECG, enzymatic, and kinetic criteria. Of the nine patients (26%) managed medically, seven patients (78%) were in cardiogenic shock (cardiac index < 2.0, left ventricular end-diastolic pressure > 25, and pulmonary edema), and all seven died in hospital. Twenty-five (74%) of the 34 patients were managed surgically or with angioplasty. Nine of these patients, of whom eight were in cardiogenic shock, also died in hospital. Regardless of the method of treatment, the presence of cardiogenic shock in this population was reproducibly a grave prognostic indicator. That is, 15 (94%) of the 16 patients in cardiogenic shock at presentation died in hospital, and only 1 (5%) of the 18 patients without cardiogenic shock died (P < .001).
CONCLUSIONS: Thus, we propose that, because patients presenting with AAMI, severe LM stenosis, and cardiogenic shock (left main shock syndrome) have such a grave prognosis regardless of management, conservative measures may be indicated.

Entities:  

Mesh:

Year:  1993        PMID: 8222198

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  Surgical revascularization for acute total occlusion of left main coronary artery.

Authors:  R B Hsu; C Y Chien; S S Wang; S H Chu
Journal:  Tex Heart Inst J       Date:  2000

2.  Evaluation of coronary artery bypass grafting in acute myocardial infarction.

Authors:  Hideyuki Fumoto; Ryuzo Sakata; Yoshihiro Nakayama; Yoshio Arai
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-08

3.  [Prognosis and management in patients with left main shock syndrome--emergency PTCA following CABG].

Authors:  H Tomioka; S Watanabe; K Hayashi; O Okada; M Minami
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-12

4.  Left main coronary artery thrombus: a case series with different outcomes.

Authors:  Rajiv Gupta; Mohammed A Rahman; Barry F Uretsky; Ernst R Schwarz
Journal:  J Thromb Thrombolysis       Date:  2005-04       Impact factor: 2.300

Review 5.  Cardiogenic shock: therapy and prevention.

Authors:  W L Barry; I J Sarembock
Journal:  Clin Cardiol       Date:  1998-02       Impact factor: 2.882

6.  Acute myocardial infarction due to left main coronary artery occlusion. Therapeutic strategy.

Authors:  Osamu Shigemitsu; Tetsuo Hadama; Shinji Miyamoto; Hirofumi Anai; Hidenori Sako; Eriko Iwata
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-04

7.  Outcome after surgery and percutaneous intervention for cardiogenic shock and left main disease.

Authors:  Michael S Lee; Chi-Hong Tseng; Colin M Barker; Venu Menon; David Steckman; Richard Shemin; Judith S Hochman
Journal:  Ann Thorac Surg       Date:  2008-07       Impact factor: 4.330

8.  The Role of the Transradial Approach for Complex Coronary Interventions in Patients with Acute Coronary Syndrome.

Authors:  Sasko Kedev
Journal:  Interv Cardiol       Date:  2013-08

9.  Successful treatment of left main shock syndrome induced by thrombosed coronary artery dissection: A case report.

Authors:  Xiaojun Bai; Weiping Zhang; Zuyi Yuan
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

10.  A successful team treatment for left main shock syndrome.

Authors:  Bin Que; Yu-Tong Cheng; Hai Gao; Xiao-Tong Hou; Ran Dong; Nan Li; Shao-Ping Nie
Journal:  J Geriatr Cardiol       Date:  2013-09       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.